跳至主要内容
临床试验/NCT01927731
NCT01927731已完成2 期

Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2013年10月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
48
试验地点
1
主要终点
Number of Participants That Achieved Platelet Engraftment Greater Than 50K/ul

研究概览

简要总结

This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.

详细描述

PRIMARY OBJECTIVES:

I. To estimate the rate of platelet engraftment by day 60 in patients undergoing cord blood transplant (CBT) or haploidentical donor stem cell transplantation treated with eltrombopag (eltrombopag olamine).

SECONDARY OBJECTIVES:

I. To assess safety of eltrombopag in this population. II. To assess neutrophil engraftment with eltrombopag in this population. III. To characterize immune reconstitution. IV. To assess overall survival (OS). V. To assess progression free survival (PFS). VI. To assess incidence of acute graft-versus-host disease (GVHD).

OUTLINE: Patients are assigned to 1 of 2 arms.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing a cord blood or haploidentical transplantation on any protocol or standard of care treatment plan.
  • Females of child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or breast-feeding must be willing to use an effective contraceptive measure until 30 days after the last dose of eltrombopag. Males who have had sexual contact with female of child-bearing potential must be willing to use contraceptive techniques until 30 days after the last dose of eltrombopag.
  • Patient or patient's legal representative(s) is/are able to provide written informed consent to participate.

排除标准

  • ALT and AST >/= 2.5 ULN.
  • Serum direct bilirubin >/= 1 mg/dl (except Gilbert's syndrome or hemolysis).
  • Patients of east Asian ancestry (Chinese, Japanese, or Korean Origin).
  • Calculated creatinine clearance < 30ml./min. Creatinine clearance will be calculated using the MDRD method.
  • Arterial or venous thrombosis in the last year except for line-related venous thrombosis more than 3 months ago.
  • Positive beta HCG within 7 days prior to consent in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or breast-feeding.

研究组 & 干预措施

Arm I (cord blood transplant patients)

Experimental

Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.

干预措施: Eltrombopag Olamine (Drug)

Arm I (cord blood transplant patients)

Experimental

Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.

干预措施: Laboratory Biomarker Analysis (Other)

Arm II (haploidentical donor stem cell transplant patients)

Experimental

Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.

干预措施: Eltrombopag Olamine (Drug)

Arm II (haploidentical donor stem cell transplant patients)

Experimental

Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.

干预措施: Laboratory Biomarker Analysis (Other)

结局指标

主要结局

Number of Participants That Achieved Platelet Engraftment Greater Than 50K/ul

时间窗: Up to day 60

Number of participants that achieved platelet engraftment greater than 50K/ul 60 days post transplant.

次要结局

  • Progression Free Survival(Up to 1 year)
  • Overall Survival(Up to 1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
2 期
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid Leukemia
NCT02071901Case Comprehensive Cancer Center31
终止
2 期
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple MyelomaMultiple MyelomaThrombocytopenia
NCT01484314Dana-Farber Cancer Institute1
已完成
2 期
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveThrombocytopeniaPrimary Myelofibrosis
NCT01428635M.D. Anderson Cancer Center21
终止
3 期
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive ProceduresChronic Liver DiseaseHCVNASH - Nonalcoholic SteatohepatitisHIV InfectionHepatitis C VirusHBVHuman Immunodeficiency VirusLiver DiseasesHepatitis B VirusNon-alcoholic SteatohepatitisThrombocytopenia
NCT00678587GlaxoSmithKline292
撤回
2 期
Study of Eltrombopag in Platelet Refractory ThrombocytopeniaThrombocytopenia
NCT01194167University of Cincinnati